ABSTRACT To investigate the mechanism of the antianginal action of diltiazem in stress-induced myocardial ischemia, we studied 12 patients with stable exertional angina and disease of the proximal left anterior descending artery by measuring great cardiac vein flow (GVCF) and calculating anterior regional coronary resistance (ARCR) during myocardial ischemia induced by atrial pacing before and after intravenous administration of diltiazem (0.25 mg/kg in a bolus dose followed by continuous infusion of 0.005 mg/kg/min). Diltiazem increased the pacing time to angina from 6.9 ± 3.5 to 10.7 + 4 min (p < .001). At peak pacing heart rate was increased after diltiazem ( Circulation 73, No. 6, 1248-1253, 1986 DILTIAZEM is a calcium channel-blocking agent that has been shown to improve exercise tolerance in patients with exertional angina.'-' It is not known, however, whether the beneficial effects of the drug are achieved by a decrease in myocardial oxygen demand at any level of exertional stress or if they are a result of an increase in coronary flow.9 In this study we evaluated the effects of diltiazem on coronary hemodynamics in a selected group of patients with stable exerciseinduced angina and disease of the proximal left anterior descending artery. Thermodilution measurements of great cardiac vein flow (GCVF), representing the venous efflux from the territory supplied by the left anterior descending artery,"'-'2 were obtained at rest and during ischemia induced by atrial pacing performed before and after intravenous administration of diltiazem. The effects of the drug on anginal threshold were then related to coronary hemodynamics and changes in oxygen consumption of the myocardial region in which perfusion was jeopardized.
DILTIAZEM is a calcium channel-blocking agent that has been shown to improve exercise tolerance in patients with exertional angina.'-' It is not known, however, whether the beneficial effects of the drug are achieved by a decrease in myocardial oxygen demand at any level of exertional stress or if they are a result of an increase in coronary flow.9 In this study we evaluated the effects of diltiazem on coronary hemodynamics in a selected group of patients with stable exerciseinduced angina and disease of the proximal left anterior descending artery. Thermodilution measurements of great cardiac vein flow (GCVF), representing the venous efflux from the territory supplied by the left anterior descending artery,"'-'2 were obtained at rest and during ischemia induced by atrial pacing performed before and after intravenous administration of diltiazem. The effects of the drug on anginal threshold were then related to coronary hemodynamics and changes in oxygen consumption of the myocardial region in which perfusion was jeopardized.
Methods
Study patients. The study group consisted of 12 patients (1 1 men and one woman, mean age 55 + 7 years) with stable exertional angina and a positive exercise test result, defined as the development of chest pain and 1 mm or more ST segment depression in the precordial leads. Patients whose angina predominantly occurred at rest or who showed ST segment elevation suggestive of variant angina were not included in this study. No patient had clinical evidence of heart failure or had had a myocardial infarction within 6 months of the study. In no patient were pathologic Q waves observed in the precordial leads. The patients underwent coronary arteriography, which revealed significant coronary artery disease (> 50% diameter narrowing of one or more vessels) that in all cases involved the proximal portion of the left anterior descending artery. No patient had left main coronary artery disease.
Procedure. All patients were studied while in the fasting state 1 to 10 days after coronary arteriography and none received premedication. Nitrates and nifedipine were suspended 12 hr before the study; four patients who were taking ,8-blockers were gradually weaned and the drug was discontinued at least 1 week before the study. When drugs were withheld we did not observe any manifestation of withdrawal phenomena, such as accelerated angina or other coronary events. None of the patients were taking verapamil or diltiazem. With patients in the supine position a triple-thermistor thermodilution catheter containing pacing electrodes'2 was inserted into the left antecubital vein and advanced under fluoroscopy into the coronary sinus with the tip positioned in the GCV. The position was confirmed by fluoroscopy and frequently checked throughout the procedure. Once the catheter was positioned, resting GCVF was determined by continuous pump infusion (per 30 sec) of a physiologic saline solution at a rate of 56 ml/min. Arterial blood pressure was recorded continuously by means of a No. 20 Teflon cannula in a brachial artery. Arterial and GCV blood samples for determination of hemoglobin oxygen saturation and lactate concentration could be obtained in eight patients. The heart rate was then increased by coronary sinus pacing in increments of 10 beats/min until the patient experienced chest pain. Each pacing rate was maintained for 2 min. When angina occurred GCVF was measured for 30 sec in all patients and repeat arterial and GCV blood samples for determination of lactate concentration and hemoglobin oxygen saturation were again obtained in eight patients. A 12-lead electrocardiogram was recorded before and at the end of pacing, and leads V4, V5, and V6 were monitored throughout the test. After a period of 40 min diltiazem was administered intravenously in a bolus dose of 0.25 mg/kg over 2 min followed by a continuous infusion of 0.005 mg/kg/min. Ten minutes later all baseline data were collected and atrial pacing was started at the same rate as used during the control pacing period. When the patient experienced chest pain or reached a heart rate of 160 beats/min, coronary hemodynamic and metabolic measurements were repeated. Venous blood samples for measuring diltiazem levels were also obtained at that time.
In those patients who developed atrioventricular block during pacing after diltiazem, atropine was given in a bolus dose of 0.5 mg. Informed consent was obtained from all patients before the study. No complications were observed during the procedure.
Calculations and statistical analysis. GCVF was calculated according to the formula: GCVF (ml/min) = Vi x [(Tb -Ti) / (Tb -Tgcv) - 1] x 1.08, where Vi is rate of injection of indicator (56 ml/min), Tb is blood temperature before injection, Ti is temperature of injectate measured by a thermistor in the lumen of the catheter during injection, Tgcv is temperature of the mixture of GCV blood and injectate, and 1.08 is a constant of the saline solution.
Mean arterial pressure was obtained by electronic filtration. Anterior regional coronary resistance (in mm Hg/ml/min) was calculated as the quotient of mean arterial pressure and GCVF. Heart rate was calculated from the electrocardiogram. The magnitude of ST segment shift was calculated by measuring the difference between the position of the ST segment (0.08 after the end of the QRS complex) during the control period and that during exercise-induced angina. Myocardial oxygen consumption of the anterior region was derived as (arterial oxygen content -GCV oxygen content) x GCVF and expressed as milliliters per minute. Plasma lactate levels were measured enzymatically. Percent lactate extraction across the anterior myocardial region was calculated as (arterial lactate -GCV lactate) x 100/arterial lactate. Plasma diltiazem levels were obtained by high-performance liquid chromatography. All results are presented as mean + SD. Statistical analysis of the resting and paced variables was performed with Student's paired t test.
Results
Cardiac catheterization and coronary arteriography. fore221 ± 38, after218 ± 35beats/min x mmHg x 10-2, p = NS). Likewise, as shown in figure 1 , no changes were observed in GCVF (before 115 + 46, after 112 ± 46 ml/min, p = NS) or anterior regional coronary resistance (before 1.3 + 0.4, after 1. 1 ± 0.4 mm Hg/ml/min, p = NS). Myocardial oxygen consumption of the anterior region at peak pacing was similar before and after the drug (before 14.5 ± 4.2, after 13.4 ± 4.7 ml/min, p = NS). Mean percent lactate extraction of the anterior region was -38 ± 26 before diltiazem and -28 ± 55 after the drug (p - '3 14 Such salutary effects may be achieved either by a reduction in myocardial oxygen consumption or by an increase in coronary flow.'5 Recent data show that diltiazem improves exercise tolerance and reduces the electrocardiographic signs of ischemia to an extent equal to or greater than moderate-dose propranolol, thus representing an effective alternative for the primary treatment of patients with stable exertional angina.' The antianginal mechanism of this drug is still under debate. Diltiazem does not increase the ratepressure product at peak exercise, indicating that a reduction in myocardial oxygen consumption is the predominant factor in the beneficial clinical effect of the drug. On the other hand, diltiazem produces less electrocardiographic ischemia than placebo for any given rate-pressure product, suggesting that the drug would increase myocardial oxygen supply.4 7 Furthermore, diltiazem has been shown to increase resting coronary flow in man as well as under experimental conditions in the presence of flow-limiting stenosis. '6 In this study we used the thermodilution technique to measure GCVF both at rest and at peak atrial pacing in 12 the presence of significant stenoses of other major coronary vessels. Thus, measurements of GCVF during atrial pacing in patients with proximal disease of the left anterior descending artery would permit the study of coronary hemoydnamic changes in a myocardial region in which perfusion is jeopardized.
Our data confirm the antianginal efficacy of diltiazem in patients with stress-induced myocardial ischemia, since mean pacing time to angina was significantly increased by intravenous administration of the drug. Since no change was observed in GCVF or anterior regional coronary resistance at rest or during peak pacing after diltiazem, as compared with the corresponding prediltiazem values, we believe that the antianginal action of the drug was mainly achieved through a reduction in myocardial metabolic demand. The decrease in systemic arterial pressure seems of crucial importance in this regard, because it offsets the higher heart rate obtained at peak pacing after diltiazem, leaving unaltered the double product, an indirect index of myocardial metabolic requirements. Moreover, myocardial oxygen consumption of the anterior region, calculated at the peak of the two pacing periods, was similar before and after the drug.
One limitation of our study is that most of our patients had multivessel disease, and thus the objection can be raised that regional ischemia could have developed during pacing in myocardial segments other than the anterior myocardium, causing angina and interruption of the test. All patients in whom blood samples could be obtained from the GCV showed lactate production at peak atrial pacing, confirming that the anterior region was really ischemic during the test. However, since we measured only regional anterior flow, we cannot rule out the possibility that diltiazem increased coronary flow in the nonanterior myocardium and that such an increase contributed to the improved performance observed after the drug. Recent data indicate that changes in coronary tone may play a pathogenetic role in the precipitation of exercise-induced angina,9 19. 20 and that antianginal drugs may improve exercise capacity by dilating the coronary stenotic segment, thereby increasing myocardial flow and oxygen delivery. studied the effects of intravenous diltiazem, given as a bolus (0.25 mg/kg) followed by continuous infusion at a rate of 0.003 mg/kg/min, on epicardial coronary arteries and stenoses in the resting state and during isometric exercise. At this dose, which is slightly lower than the dose used in our study and was chosen to achieve steady-state plasma levels similar to those obtained with an oral dose of 360 mg/day,6 diltiazem did not induce any significant change in the mean crosssectional area of diseased coronary segments, but was able to prevent the a-mediated coronary vasoconstriction induced by isometric exercise. This suggests that diltiazem could also improve myocardial blood flow during dynamic exercise, although isometric exercise is characterized by a more intense and widespread vasoconstriction than dynamic exercise.2' Moreover, data from our group suggest that coronary vasodilatation occurs during dynamic exercise22 even in presence of a cold pressor test, a strong a-vasoconstrictor stimulus. 23 Further studies are needed to clarify if a-mediated coronary vasoconstriction could play a role in the pathogenesis of myocardial ischemia induced by dynamic exercise.
In conclusion, although our data do not permit us to exclude the possibility that diltiazem might improve exercise capacity in some patients by increasing coronary flow in ischemic myocardial regions, they seem to indicate that reduction of myocardial oxygen con-sumption plays a major role in the antianginal action of diltiazem in patients with stable exertional angina.
